Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05053828 · ClinicalTrials.gov registry record

Type 2 Diabetes With Antiplatelet Drugs

A clinical trial of Heart Failure and Type 2 Diabetes, sponsored by Tabula Rasa HealthCare.

Completed
Registry status
173,464
Enrollment target
1
Study location

NCT05053828: Completed study of Heart Failure and Type 2 Diabetes, sponsored by Tabula Rasa HealthCare.

NCT05053828 is a study of Heart Failure and Type 2 Diabetes that has completed, run by Tabula Rasa HealthCare. The registered enrollment target is 173,464 participants, above the 1,612-participant average among 397 other Heart Failure trials with a reported enrollment target (10661% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05053828, a study of Heart Failure and Type 2 Diabetes, has completed, sponsored by Tabula Rasa HealthCare.

COMPLETED
Registry status
173,464 participants
Enrollment target
1
Study location

Study Summary

Tabula Rasa HealthCare (TRHC), d/b/a CareKinesis, is the first national pharmacy that provides science-based medication risk identification and mitigation technologies and services. CareKinesis utilizes medication decision support tools and pharmacists certified in geriatrics to provide pharmacy services for various healthcare organizations including PACE organizations (described above). Presently, CareKinesis services more than 35 PACE organizations, including approximately 140 PACE sites, across the country. As a national PACE pharmacy provider since 2011, CareKinesis focuses on improving medication regimens to reduce medication-related risks while enhancing economic, clinical and humanistic outcomes. Pharmacist-led clinical services and medication safety reviews are currently being offered to PACE organizations under the direction of licensed healthcare prescribers by TRHC (CareKinesis). Through mutual data-sharing agreements, patient data will be collected retrospectively for patients satisfying the inclusion and exclusion criteria. TRHC via other programs such as the Center for Medicare \& Medicaid Enhanced Medication Therapy Management program with BlueCross BlueShield Northern Plain Alliance and ClearStone, or via collaboration as third party with other health plans can have access to de-identified patient's data. TRHC has also established an agreement with the Watson IBM database to retrieve relevant patients' information for research.

Primary Outcome

Quantitative

Interventions

  • DRUG Antiplatelet Drug

Study Locations (1)

Florida

  • Tabula Rasa Healthcare - Orlando

Trial Details

FieldValue
Enrollment Target 173,464 participants
Start Date 2021-09-20
Est. Completion 2023-01-30
Tabula Rasa HealthCare

5 total trials

What the finished NCT05053828 record still lists

NCT05053828 is an observational study that tracks outcomes without assigning an intervention. Its 173,464 participants enrollment target places it among the larger protocols in the corpus, above the 1,612-participant average among 397 other Heart Failure trials with a reported enrollment target (10661% higher).

The record links to 4 conditions, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which Antiplatelet Drug is the first listed.

NCT05053828 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT05053828 about?

NCT05053828 is a clinical study titled "Type 2 Diabetes With Antiplatelet Drugs". Tabula Rasa HealthCare (TRHC), d/b/a CareKinesis, is the first national pharmacy that provides science-based medication risk identification and mitigation technologies and services. CareKinesis utilizes medication decision support tools and pharmacists certified in geriatrics to provide pharmacy ser...

What is the current status of trial NCT05053828?

This trial is currently completed. The enrollment target is 173,464 participants. The study started on 2021-09-20. Estimated completion is 2023-01-30.

What conditions does trial NCT05053828 study?

This clinical trial studies the following conditions: Heart Failure, Type 2 Diabetes, Myocardial Infarction, Antiplatelet Drugs.

What interventions are being tested in trial NCT05053828?

The interventions under investigation include: Antiplatelet Drug (DRUG).

Who is sponsoring clinical trial NCT05053828?

This trial is sponsored by Tabula Rasa HealthCare, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05053828 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05053828's enrollment target sits among peer trials

173,464 1st of 397 higher than 397 of 397 other Heart Failure trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06090578 · 180,000 participants · NA

    TabCAT Brain Health Assessment in Primary Care

  • NCT06917339 · 156,000 participants

    Retrospective Analyses of TrakStar Database

  • NCT06232551 · 152,000 participants · NA

    Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism

  • NCT05994482 · 130,000 participants

    Surveillance Colonoscopy in Older Adults: The SurvOlderAdults Study

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05053828, the US trial registry maintained by the National Library of Medicine. NCT05053828 (large enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.